U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H28ClN3O.2H3O4P
Molecular Weight 605.942
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NAPHTHOQUINE PHOSPHATE

SMILES

OP(O)(O)=O.OP(O)(O)=O.CC(C)(C)NCC1=CC(NC2=CC=NC3=CC(Cl)=CC=C23)=C4CCCCC4=C1O

InChI

InChIKey=QTYPWHKJEDCDNH-UHFFFAOYSA-N
InChI=1S/C24H28ClN3O.2H3O4P/c1-24(2,3)27-14-15-12-22(17-6-4-5-7-18(17)23(15)29)28-20-10-11-26-21-13-16(25)8-9-19(20)21;2*1-5(2,3)4/h8-13,27,29H,4-7,14H2,1-3H3,(H,26,28);2*(H3,1,2,3,4)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22363211

Naphthoquine is an antimalarial drug first synthesized in China in 1986 but which was not developed for clinical use until the late 1990s. This drug now is used in combination for treatment of Plasmodium Falciparum and Malaria. The use of anti-malarial drug combinations with artemisinin or with one of its derivatives is now widely recommended to overcome drug resistance in falciparum as well as vivax malaria. The fixed oral dose artemisinin-naphthoquine combination (ANQ, ARCO™) is a newer artemisinin-based combination (ACT) therapy undergoing clinical assessment.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
various P. falciparum strains
2
Target ID: various P. falciparum strains
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Phase IV
63
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Open-label trial of three dosage regimens of fixed-dose combination of artemisinin and naphthoquine for treating uncomplicated falciparum malaria in Calabar, Nigeria.
2012 Dec 11
Naphthoquine: An Emerging Candidate for Artemisinin Combination Therapy.
2016 May

Sample Use Guides

In Vivo Use Guide
Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision. Each tablet of ARCO(artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet). The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet)).
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
NAPHTHOQUINE PHOSPHATE
WHO-DD  
Common Name English
Naphthoquine phosphate [WHO-DD]
Common Name English
1-NAPHTHALENOL, 4-((7-CHLORO-4-QUINOLINYL)AMINO)-2-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-5,6,7,8-TETRAHYDRO-, PHOSPHATE (1:2) (SALT)
Systematic Name English
4-(7-CHLORO-4-AMINOQUINOLINE)-2-TERT-BUTYLAMINOMETHYL-5,6,7,8-4HYDRO-1-NAPHTHOL DIPHOSPHATE
Systematic Name English
Code System Code Type Description
CAS
173531-58-3
Created by admin on Sat Dec 16 09:21:56 GMT 2023 , Edited by admin on Sat Dec 16 09:21:56 GMT 2023
PRIMARY
PUBCHEM
9851774
Created by admin on Sat Dec 16 09:21:56 GMT 2023 , Edited by admin on Sat Dec 16 09:21:56 GMT 2023
PRIMARY
EPA CompTox
DTXSID70431766
Created by admin on Sat Dec 16 09:21:56 GMT 2023 , Edited by admin on Sat Dec 16 09:21:56 GMT 2023
PRIMARY
FDA UNII
M6M6AP4KAH
Created by admin on Sat Dec 16 09:21:56 GMT 2023 , Edited by admin on Sat Dec 16 09:21:56 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of NAPHTHOQUINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966